Acumen Showcases Advances in Alzheimer’s Research at Global

Acumen Pharmaceuticals said it will present new research on its Alzheimer’s treatment candidate at the International Conference on Alzheimer’s and Parkinson’s Diseases 2026 in Copenhagen.

The company will include one oral session and two posters highlighting advances in enhanced brain delivery (EBD™) of sabirnetug, biomarker treatment responses, and the development of new antibodies targeting soluble amyloid beta oligomers linked to Alzheimer’s disease, they said.

“The data we’re presenting reflects our dedication to finding better solutions for Alzheimer’s patients and their families,” said Jim Doherty, President and Chief Development Officer of Acumen. “By exploring enhanced brain delivery methods and developing more selective antibodies, we’re working toward treatments that could potentially improve effectiveness and safety, while expanding convenience and supporting a wider range of people impacted by Alzheimer’s disease.”